Sanofi announced that at its meeting held on February 6, 2019, the Board of Directors duly noted the resignation of Mr. Mulliez and decided, after consultation of the Appointments and Governance Committee, to co-opt Christophe Babule as Director for the remainder of Christian Mulliez's term of office (expiring at the end of the annual shareholders' meeting held in 2022 to approve the financial statements for the fiscal year ending December 31, 2021). The co-optation of Christophe Babule will be subject to ratification by the next shareholders' meeting of Sanofi, on April 30, 2019.